Rijksvaccinatieprogramma LIM cohortstudie: RVP monitor

First published: 03/03/2022

Last updated: 14/03/2024





Administrative details

EU PAS number	
EUPAS45669	
Study ID	
45670	
_	
DARWIN EU® study	
No	
Study countries	
Netherlands	
iverilenatius	

Study status

Ongoing

Research institutions and networks

Institutions

Netherlands Pharmacovigilance Centre Lareb				
☐ Netherlands				
First published: 05/02/2010				
Last updated: 19/07/2016				
Institution Outdated Not-for-profit ENCePP partner				

Contact details

Study institution contact

Helen Gosselt h.gosselt@lareb.nl

Study contact

h.gosselt@lareb.nl

Primary lead investigator

Agnes Kant

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 11/03/2020

Actual: 11/03/2020

Study start date

Planned: 01/01/2022 Actual: 11/01/2022

Date of final study report

Planned: 01/04/2026

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Ministry of Health, Welfare and Sports

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

www.rvpmonitor.nl

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Main study objective:

To investigate the presence of adverse events following immunization (AEFI) for every vaccin, within the Dutch National Immunization Programme, in children between 0 and 4 years old. In addition, we investigate the impact and course of the AEFIs as well as the risk of recurrence of AEFIs for multidose vaccines.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(J07AL01) pneumococcus, purified polysaccharides antigen pneumococcus, purified polysaccharides antigen

(J07CA09) diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanushepatitis B

diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B (J07BD52) measles, combinations with mumps and rubella, live attenuated measles, combinations with mumps and rubella, live attenuated (J07AH08) meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated

meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated

(J07CA02) diphtheria-pertussis-poliomyelitis-tetanus diphtheria-pertussis-poliomyelitis-tetanus

Population studied

Age groups

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Special population of interest

Pregnant women

Estimated number of subjects

5000

Study design details

Outcomes

- Which AEFI's occur after each vaccination, - What is the course and impact of these AEFIs - Do AEFI's reccur after multidose vaccinations and if so, which AEFIs? - Are there any riskfactors to experience (recurring) AEFIs?

Data analysis plan

- Cross-sectional analysis on the number of experienced AEFI's per vaccin (frequencies) - Longitudinal analyses on the recurrence of AEFI's (compare frequencies for multidose vaccinations) - Regression analysis to investigate risk

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

П	ln	V	n	\cap	۱۸	n
u	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ĸ		()	vv	

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No